

Modulation of ERK and AKT pathways as the potential therapeutic targets for *Toxoplasma gondii* infection

Razieh Hosseini* and Negar Panahi

Department of Veterinary Basic Sciences, Science and Research Branch, Islamic Azad University, Tehran, Iran

Article type:

Mini-review article

Keywords:

Toxoplasma gondii
PI3Ks
Akt
Parasitic diseases
Congenital toxoplasmosis

Article history:

Received:

February 23, 2024

Revised:

March 10, 2024

Accepted:

March 12, 2024

Available online:

March 30, 2024

Abstract

Toxoplasmosis is a zoonotic disease caused by *Toxoplasma gondii*, which can infect humans through oocysts or undercooked meat. It can cause varying symptoms, including congenital toxoplasmosis. Early detection and treatment are beneficial, and antimicrobial treatment can prevent or resolve symptoms. The disease has a complex life cycle, with felids being the definitive host. Understanding the signaling pathways is crucial for effective therapeutic strategies. Toxoplasma invasion is regulated by the microtubule cytoskeleton, affecting macrophages and innate immunity cells. Calcium binding proteins and focal adhesion kinase-2 have been identified as key regulators of calcium signaling in Toxoplasma. Calcium signaling is crucial for parasite biology and drug development. The ERK pathway plays a significant role in host-parasite interactions and immune responses. This pathway plays a critical role in the spread of Toxoplasma by manipulating host cell migration. Toxoplasma infection can activate the ERK signaling pathway, leading to the inhibition of apoptosis in host cells. This inhibition of apoptosis is believed to have a positive effect on the survival and replication of the parasite in the host. The Akt signaling pathway, also known as the PI3K/Akt pathway, is crucial in parasitic diseases, modulating host immune responses and parasite survival. Host AKT activation is important for *T. gondii* proliferation which is related to reduction of ROS in host cells. More investigation is required to fully understand how these signals contribute to the pathophysiology of Toxoplasma infection and to identify possible therapeutic targets for the management of parasitic illnesses.

Introduction

Toxoplasma gondii is the parasite that causes the zoonotic disease toxoplasmosis. Many warm-blooded animals, including humans, are susceptible to infections (1). Consumption of undercooked meat containing tissue cysts or ingestion of oocysts

excreted in the feces of infected cats is the main routes of transmission of the disease to humans (2). In humans, toxoplasmosis can have different manifestations depending on the individual immune response (3). Congenital toxoplasmosis is of particular concern as it can lead to serious

*Corresponding author: razieh.hosseini@iaau.ac.ir

<https://doi.org/10.22034/jzd.2024.17741>

https://jzd.tabrizu.ac.ir/article_17741.html

Cite this article: Hosseini R. and Panahi N. Modulation of ERK and AKT pathways as the potential therapeutic targets for *Toxoplasma gondii* infection. *Journal of Zoonotic Diseases*, 2024, 8 (2): x-x

Copyright© 2024, Published by the University of Tabriz.

This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International (CC BY NC)



complications in newborns (4). Early detection of infection during pregnancy and timely initiation of treatment have been associated with favorable outcomes (5). Studies have shown that active infections can be treated, and antimicrobial treatment of *T. gondii* in animal models has resulted in the prevention or elimination of disease symptoms (6). Toxoplasmosis can also affect the central nervous system (CNS). The manifestations of CNS toxoplasmosis can vary depending on the immune response of the individual (7). In immunocompromised individuals, such as HIV/AIDS patients, toxoplasmosis can cause severe neurological symptoms, including encephalitis and brain abscesses (8).

T. gondii has a complex life cycle that includes both sexual and asexual phases. The feline family, particularly cats, is the definitive host of *T. gondii*, where the sexual cycle occurs (9). Humans and other warm-blooded animals are intermediate hosts for the asexual cycle. The asexual cycle begins when an intermediate host ingests oocysts excreted in the feces of the infected cats or by consuming uncooked meat containing tissue cysts. Once inside the host, the oocysts release sporozoites that invade the host cells and differentiate into tachyzoites. Tachyzoites proliferate rapidly in host cells and cause acute infection (10). During acute infection, tachyzoites can spread throughout the host's body and invade various tissues and organs (11). They can also cross the placenta and cause congenital infections in pregnant women (12). Under certain conditions, such as immune pressure or stress, tachyzoites can differentiate into bradyzoites and form tissue cysts. These cysts develop mainly in the brain, muscles, and other tissues and lead to chronic infections (13). The cysts can remain in the host for life. When an intermediate host is eaten by a cat, the cysts are digested, releasing bradyzoites that can reproduce sexually in the cat's intestines. This leads to the production of oocysts, which are excreted in the feces and complete the sexual cycle (14). The life cycle of *T. gondii* involves a delicate balance between the parasite and the host's immune

response. The parasite uses various mechanisms to escape the host's immune system and cause a chronic infection (15).

***T. gondii* modulates signaling pathways to invade host cells**

The obligate intracellular parasite *T. gondii* infects a significant proportion of the world's population (16). Understanding the signaling pathways involved in the interaction between *Toxoplasma* and its host is crucial for elucidating the mechanisms of infection and developing effective therapeutic strategies. *T. gondii* modulates host cell responses and manipulates host cell physiology to provide survival advantages (17). Invasion of host cells by *Toxoplasma* involves a complex process consisting of parasite contact, attachment, motility, and penetration (18). Several studies have focused on the regulation of apoptosis pathways and impairment of host cell immunity, signaling, and invasion mechanisms by *Toxoplasma* (19).

One study found that induction of dendritic cell (DC) migration following *Toxoplasma* infection increased parasite dissemination (20). The migration of *Toxoplasma*-infected DCs depended on live intracellular parasites and the G Protein Coupled Receptor (GPCR) signaling pathway, but not on specific chemokine receptors or Toll/interleukin-1 receptor signaling (20). In vivo, *Toxoplasma*-infected DCs reached the mesenteric lymph nodes and spleen in similar or higher numbers than lipopolysaccharide-stimulated DCs (21). *Toxoplasma* invasion is temporally regulated by the host microtubule cytoskeleton (22). The initial interaction between *Toxoplasma* and host cells is mediated by surface antigens of the parasite, resulting in a loose, low-affinity contact (22). Activation of the invasion motor and release of apical organelles in *Toxoplasma* depend on calcium-dependent signal transduction pathways (23). *Toxoplasma* infection also affects host cell signaling, particularly in macrophages and other cells of innate immunity (24). The parasite suppresses pro-inflammatory cytokine responses in

macrophages, leading to dysregulation of host cell signaling (24). Furthermore, the absence of profilin, an actin-binding molecule, in *Toxoplasma* impairs parasite motility and host cell invasion (25). Invasion of host cells by *Toxoplasma* is accompanied by changes in the parasite's gene expression, reflecting a switch from proteins involved in invasion and motility to proteins involved in metabolism and DNA replication (26). This switch in gene expression is related to the establishment of the intracellular environment and the unique relationship between the G1 phase and invasion (27).

An important signaling pathway associated with *Toxoplasma* infection is the calcium signaling pathway. Calcium signaling plays a crucial role in various processes during the lytic cycle of *Toxoplasma*, including invasion, egress, and replication of the parasite (28). Calcium binding proteins and focal adhesion kinase-2 have been identified as key regulators of calcium signaling in *Toxoplasma* (28). The discovery of new players in calcium signaling not only improves our understanding of the biology of these parasites but also provides potential targets for the development of drugs, vaccines, and diagnostic tools (28).

ERK and Akt signaling pathways targeted by *T. gondii*

The extracellular signal-regulated kinase (ERK) signaling pathway, also called as the mitogen-activated protein kinase (MAPK/ERK) pathway (Figure 1), is a highly conserved intracellular signaling pathway involved in cell proliferation, differentiation and survival. It is activated by numerous extracellular stimuli, including growth factors, cytokines, and environmental stressors. Upon stimulation, ERK phosphorylates and activates downstream targets, including transcription factors, leading to the regulation of gene expression (29). In the context of parasitic diseases, the ERK signaling pathway has been linked to host-parasite interactions and the modulation of immune responses (30). For

example, in malaria, *Plasmodium falciparum* infection has been shown to activate the ERK signaling pathway in host immune cells such as monocytes and macrophages. This activation contributes to the production of pro-inflammatory cytokines and the regulation of the immune response against the parasite (31). Similarly, the ERK signaling pathway was found to be involved in modulating the host immune response during *Leishmania* infection. Studies have shown that *Leishmania* parasites can activate the ERK pathway in host macrophages, leading to the production of anti-inflammatory cytokines and suppression of host immune defenses (32). Besides its function in immune regulation, the ERK signaling pathway may also be involved in intracellular survival and replication of parasites. For example, during *T. gondii* infection, activation of ERK signaling was associated with inhibition of apoptosis in host cells, promoting survival and replication of the parasite (33). Overall, the ERK signaling pathway plays an important role in parasitic diseases by modulating the host immune response, promoting parasite survival, and potentially influencing disease progression.

A study by Lambert et al. (2006) focused on the induction of dendritic cell (DC) migration during *T. gondii* infection and its impact on parasite dissemination. The transmigration of infected DC across endothelial cell monolayers was made possible by the active invasion of DC by *Toxoplasma*, which the authors found to induce a state of hypermotility. This migration was found to be dependent on ERK signaling, as inhibition of ERK activation significantly reduced the migration of infected DC (20). These results suggest that ERK signaling plays a critical role in the spread of *Toxoplasma* by manipulating host cell migration. Another study by Mammari et al. (2019) provided an overview of the apoptotic pathways modulated by *T. gondii*. The authors reported that *Toxoplasma* infection can activate the ERK signaling pathway, leading to the inhibition of apoptosis in host cells. This inhibition of apoptosis is believed to have a

positive effect on the survival and replication of the parasite in the host. The study also highlighted the involvement of other signaling pathways such as Phosphoinositide 3-kinases (PI3Ks), Akt (protein kinase B) (PI3K/AKT) and c-Jun N-terminal kinase (JNK) in the modulation of apoptosis by *Toxoplasma* (19). In a previous study, the intracellular connections of the PI3K/AKT and

MAPK signaling pathways in the regulation of *Toxoplasma*-induced interleukin (IL)-23 and IL-12 production in human THP-1 cells are discussed. This study highlights the involvement of TLR2 and TLR4 in cytokine production and the role of PI3K and MAPK signaling pathways in modulating IL-23 and IL-12 production (34).




Fig. 1. ERK and Akt signaling pathways targeted by *T. gondii*

The Akt signaling pathway, also called the PI3K/Akt pathway, is a critical intracellular signaling pathway involved in several cellular processes, including cell survival, cell proliferation, growth and metabolism. This signaling pathway has been extensively studied in the context of parasitic diseases and demonstrated its importance in host-parasite interactions and disease pathogenesis (35). In the context of parasitic diseases, the Akt signaling pathway is involved in modulating the host immune response and parasite survival. For

example, in malaria, *P. falciparum* infection has been shown to activate the Akt pathway in the host's immune cells, leading to the production of pro-inflammatory cytokines and the regulation of immune responses against the parasite (36). In *Leishmania* infection, the Akt signaling pathway was found to play a role in the survival and replication of the parasite in host cells. Studies have shown that *Leishmania* parasites can activate Akt signaling in the infected macrophages, promote cell survival, and inhibit apoptosis. This activation of

Akt contributes to the establishment and persistence of the infection (37). In the context of *Toxoplasma* infection, *T. gondii* activates the AKT pathway in a dose-dependent manner through toll-like receptors (TLR) 2 and TLR4 (19). The AKT pathway's activation may contribute to the modulation of apoptosis and the persistence of *Toxoplasma* in host cells. Apart from its role in apoptosis regulation, the AKT pathway has also been implicated in other cellular processes relevant to *Toxoplasma* infection. For instance, long-term depression mediated by metabotropic glutamate receptors in the mouse hippocampus requires activation of PI3-kinase and AKT (38). This suggests that the AKT pathway may play a role in synaptic plasticity and neuronal function, which may be relevant to the neurological manifestations of *Toxoplasma* infection. A study by Yu et al. (2015) provides insights into the role of Akt isoforms in vascular diseases. While this reference does not specifically focus on parasitic diseases, it highlights the importance of Akt isoforms in various cellular processes relevant to parasitic infections, such as cell movement, proliferation, and signal transduction. The study highlights that the three Akt isoforms (Akt1, Akt2, and Akt3) have different tissue expression profiles and can have different functions in different cell types (39). A study by Karanovic et al. (2019) examined the association between PI3K and *Toxoplasma* infection in patients with activated PI3-kinase δ syndrome type 2 (APDS2). The authors reported that *T. gondii* can evade host defense by activating the PI3K/AKT signaling pathway, which decreases intracellular reactive oxygen species (ROS) through NOX4 suppression. This activation of the PI3K/AKT pathway leads to phosphorylation and inactivation of the transcription factor FOXO1, thereby preventing the transcription of p22 phox, a component of the NADPH oxidase complex involved in ROS production (40). These studies suggest that PI3K plays a role in *Toxoplasma* infections by modulating host immune responses. Stimulation of the PI3K/AKT signaling pathway by

T. gondii could help the parasite evade host defense mechanisms by reducing ROS production. Furthermore, PI3K appears to be involved in the regulation of cytokine production during *Toxoplasma* infection, with inhibition of PI3K leading to a reduction in IL-23 production.

Conclusion

The intracellular parasite *Toxoplasma gondii* induces host AKT activation to prevent autophagy-mediated clearance. Cellular MAP Kinases (ERK, P38, JNKs) are also activated during the parasite invasion. In summary, ERK and PI3K/AKT signaling play an important role in *Toxoplasma* infections by influencing host immune responses, facilitating the spread of the parasite and also contributing to the inhibition of apoptosis in host cells, thereby improving survival and promotes parasite replication and cytokine production. More investigation is required to fully understand the ways in which these signals contribute to the pathophysiology of *Toxoplasma* infection and to identify possible therapeutic targets for the management of parasitic illnesses.

Acknowledgements

Not applicable.

Ethical approval

Not applicable.

Conflict of interest

The authors declared no conflict of interest.

References

1. de Barros RA, Torrecilhas AC, Marciano MA, Mazuz ML, Pereira-Chiocola VL, Fux B. Toxoplasmosis in human and animals around the world. Diagnosis and perspectives in the one health approach. *Acta Trop.* 2022 Jul 1;231:106432. <https://doi.org/10.1016/j.actatropica.2022.106432>
2. Almeria S, Dubey JP. Foodborne transmission of *Toxoplasma gondii* infection in the last decade. An overview. *Res Vet Sci.* 2021 Mar 1;135:371-85. <https://doi.org/10.1016/j.rvsc.2020.10.019>

3. Graham A, Fong C, Naqvi A, Lu JQ. Brain Toxoplasmosis Comorbid with Autoimmune Disease: Complicated Immune Response And Case Demonstration. *CJNS*. 2021 Jul;48(s2):S8-S8. <https://doi.org/10.1017/cjn.2021.164>
4. Dubey JP, Murata FH, Cerqueira-Cézar CK, Kwok OC, Villena I. Congenital toxoplasmosis in humans: an update of worldwide rate of congenital infections. *Parasitology*. 2021 Oct;148(12):1406-16. <https://doi.org/10.1017/s0031182021001013>
5. Mandelbrot L. Congenital toxoplasmosis: What is the evidence for chemoprophylaxis to prevent fetal infection?. *Prenat Diagn*. 2020 Dec;40(13):1693-702. <https://doi.org/10.1002/pd.5758>
6. Konstantinovic N, Guegan H, Stājner T, Belaz S, Robert-Gangneux F. Treatment of toxoplasmosis: Current options and future perspectives. *Food Waterborne Parasitol*. 2019 Jun 1;15:e00036. <https://doi.org/10.1016/j.fawpar.2019.e00036>
7. Graham AK, Fong C, Naqvi A, Lu JQ. Toxoplasmosis of the central nervous system: Manifestations vary with immune responses. *J Neurol Sci*. 2021 Jan 15;420:117223. <https://doi.org/10.1016/j.jns.2020.117223>
8. Dian S, Ganiem AR, Ekawardhani S. Cerebral toxoplasmosis in HIV-infected patients: a review. *Pathog Glob Health*. 2023 Jan 2;117(1):14-23. <https://doi.org/10.1080/20477724.2022.2083977>
9. Galal L, Arieu F, Gouilh MA, Dardé ML, Hamidović A, Letourneur F, et al. A unique *Toxoplasma gondii* haplotype accompanied the global expansion of cats. *Nat Commun*. 2022 Oct 1;13(1):5778. <https://doi.org/10.1038/s41467-022-33556-7>
10. Attias M, Teixeira DE, Benchimol M, Vommaro RC, Crepaldi PH, De Souza W. The life-cycle of *Toxoplasma gondii* reviewed using animations. *Parasite Vectors*. 2020 Dec;13:1-3. <https://doi.org/10.1186/s13071-020-04445-z>
11. Tomasina R, Francia ME. The structural and molecular underpinnings of gametogenesis in *Toxoplasma gondii*. *Front Cell Infect Microbiol*. 2020 Dec 7;10:608291. <https://doi.org/10.3389/fcimb.2020.608291>
12. Deganich M, Boudreaux C, Benmerzouga I. Toxoplasmosis infection during pregnancy. *Trop Med Infect Dis*. 2022 Dec 21;8(1):3. <https://doi.org/10.3390/tropicalmed8010003>
13. Zhao XY, Ewald SE. The molecular biology and immune control of chronic *Toxoplasma gondii* infection. *J Clin Invest*. 2020 Jul 1;130(7):3370-80. <https://doi.org/10.1172/jci136226>
14. Hatam-Nahavandi K, Calero-Bernal R, Rahimi MT, Pagheh AS, Zarean M, Dezhkam A, Ahmadvour E. *Toxoplasma gondii* infection in domestic and wild felids as public health concerns: a systematic review and meta-analysis. *Sci Rep*. 2021 May 4;11(1):9509. <https://doi.org/10.1038/s41598-021-89031-8>
15. Sana M, Rashid M, Rashid I, Akbar H, Gomez-Marin JE, Dimier-Poisson I. Immune response against toxoplasmosis—some recent updates RH: *Toxoplasma gondii* immune response. *Int J Immunopathol Pharmacol*. 2022 Feb 7;36:03946320221078436. <https://doi.org/10.1177/03946320221078436>
16. Kakakhel MA, Wu F, Anwar Z, Saif I, ul Akbar N, Gul N, et al. The presence of *Toxoplasma gondii* in soil, their transmission, and their influence on the small ruminants and human population: A review. *Microb Pathog*. 2021 Sep 1;158:104850. <https://doi.org/10.1016/j.micpath.2021.104850>
17. Rashidi S, Mansouri R, Ali-Hassanzadeh M, Mojtahedi Z, Shafiei R, Savardashtaki A, et al. The host mTOR pathway and parasitic diseases pathogenesis. *Parasitol Res*. 2021 Apr;120:1151-66. <https://doi.org/10.1007/s00436-021-07070-6>
18. Venugopal K, Chehade S, Werkmeister E, Barois N, Periz J, Lafont F, Tardieux I, Khalife J, et al. Rab11A regulates dense granule transport and secretion during *Toxoplasma gondii* invasion of host cells and parasite replication. *PLoS Pathog*. 2020 May 28;16(5):e1008106. <https://doi.org/10.1371/journal.ppat.1008106>
19. Mammari N, Halabi MA, Yaacoub S, Chlala H, Dardé ML, Courtioux B. *Toxoplasma gondii* modulates the host cell responses: an overview of apoptosis pathways. *Biomed Res Int*. 2019 Apr 4;2019. <https://doi.org/10.1155/2019/6152489>
20. Lambert H, Hitziger N, Dellacasa I, Svensson M, Barragan A. Induction of dendritic cell

- migration upon *Toxoplasma gondii* infection potentiates parasite dissemination. *Cell Microbiol.* 2006 Oct;8(10):1611-23. <https://doi.org/10.1111/j.1462-5822.2006.00735.x>
21. Lambert H, Barragan A. Modelling parasite dissemination: host cell subversion and immune evasion by *Toxoplasma gondii*. *Cell Microbiol.* 2010 Mar;12(3):292-300. <https://doi.org/10.1111/j.1462-5822.2009.01417.x>
 22. Sweeney KR, Morrissette NS, LaChapelle S, Blader IJ. Host cell invasion by *Toxoplasma gondii* is temporally regulated by the host microtubule cytoskeleton. *Eukaryot Cell.* 2010 Nov;9(11):1680-9. <https://doi.org/10.1128/ec.00079-10>
 23. Lourido S, Moreno SN. The calcium signaling toolkit of the Apicomplexan parasites *Toxoplasma gondii* and *Plasmodium* spp. *Cell Calcium.* 2015 Mar 1;57(3):186-93. <https://doi.org/10.1016/j.ceca.2014.12.010>
 24. Ahmadpour E, Babaie F, Kazemi T, Mehrani Moghaddam S, Moghimi A, Hosseinzadeh R, Nissapatorn V, Pagheh AS. Overview of apoptosis, autophagy, and inflammatory processes in *Toxoplasma gondii* infected cells. *Pathogens.* 2023 Feb 4;12(2):253. <https://doi.org/10.3390/pathogens12020253>
 25. Bisio H, Soldati-Favre D. Signaling cascades governing entry into and exit from host cells by *Toxoplasma gondii*. *Annu Rev Microbiol.* 2019 Sep 8;73:579-99. <https://doi.org/10.1146/annurev-micro-020518-120235>
 26. Li W, Grech J, Stortz JF, Gow M, Periz J, Meissner M, Jimenez-Ruiz E. A splitCas9 phenotypic screen in *Toxoplasma gondii* identifies proteins involved in host cell egress and invasion. *Nat Microbiol.* 2022 Jun;7(6):882-95. <https://doi.org/10.1038/s41564-022-01114-y>
 27. Sharma J, Rodriguez P, Roy P, Guiton PS. Transcriptional ups and downs: patterns of gene expression in the life cycle of *Toxoplasma gondii*. *Microbes Infect.* 2020 Nov 1;22(10):525-33. <https://doi.org/10.1016/j.micinf.2020.09.001>
 28. Triana MA, Márquez-Nogueras KM, Vella SA, Moreno SN. Calcium signaling and the lytic cycle of the Apicomplexan parasite *Toxoplasma gondii*. *Biochim Biophys Acta Mol Cell Res.* 2018 Nov 1;1865(11):1846-56. <https://doi.org/10.1016/j.bbamcr.2018.08.004>
 29. Wen X, Jiao L, Tan H. MAPK/ERK pathway as a central regulator in vertebrate organ regeneration. *Int J Mol Sci.* 2022 Jan 27;23(3):1464. <https://doi.org/10.3390/ijms23031464>
 30. Paul S, Ruiz-Manriquez LM, Serrano-Cano FI, Estrada-Meza C, Solorio-Diaz KA, Srivastava A. Human microRNAs in host-parasite interaction: a review. *3 Biotech.* 2020 Dec;10:1-6. <https://doi.org/10.1007/s13205-020-02498-6>
 31. Adderley JD, John von Freyend S, Jackson SA, Bird MJ, Burns AL, Anar B, et al. Analysis of erythrocyte signalling pathways during *Plasmodium falciparum* infection identifies targets for host-directed antimalarial intervention. *Nat Commun.* 2020 Aug 11;11(1):4015. <https://doi.org/10.1038/s41467-020-17829-7>
 32. Liu D, Uzonna JE. The early interaction of *Leishmania* with macrophages and dendritic cells and its influence on the host immune response. *Front Cell Infect Microbiol.* 2012 Jun 12;2:83. <https://doi.org/10.3389/fcimb.2012.00083>
 33. Zhao Y, Gui W, Niu F, Chong S. The MAPK signaling pathways as a novel way in regulation and treatment of parasitic diseases. *Diseases.* 2019 Jan 17;7(1):9. <https://doi.org/10.3390/diseases7010009>
 34. Quan JH, Chu JQ, Kwon J, Choi IW, Ismail HA, Zhou W, et al. Intracellular networks of the PI3K/AKT and MAPK pathways for regulating *Toxoplasma gondii*-induced IL-23 and IL-12 production in human THP-1 cells. *PLoS One.* 2015 Nov 3;10(11):e0141550. <https://doi.org/10.1371/journal.pone.0141550>
 35. Choi HG, Gao FF, Zhou W, Sun PR, Yuk JM, Lee YH, et al. The role of PI3K/AKT pathway and NADPH oxidase 4 in host ROS manipulation by *Toxoplasma gondii*. *Korean J Parasitol.* 2020 Jun;58(3):237. <https://doi.org/10.3347/kjp.2020.58.3.237>
 36. Hun LV, Cheung KW, Brooks E, Zudekoff R, Luckhart S, Riehle MA. Increased insulin signaling in the *Anopheles stephensi* fat body regulates metabolism and enhances the host response to both bacterial challenge and *Plasmodium falciparum* infection. *Insect*

- Biochem Mol Biol. 2021 Dec 1;139:103669. <https://doi.org/10.1016/j.ibmb.2021.103669>
37. Ranatunga M, Rai R, Richardson SC, Dyer P, Harbige L, Deacon A, et al. Leishmania aethiopica cell- to- cell spreading involves caspase- 3, Akt, and NF- κ B but not PKC- δ activation and involves uptake of LAMP- 1- positive bodies containing parasites. FEBS J. 2020 May;287(9):1777-97. <https://doi.org/10.1111/febs.15166>
38. Emamian ES. AKT/GSK3 signaling pathway and schizophrenia. Front Mol Neurosci. 2012 Mar 15;5:33. <https://doi.org/10.3389/fnmol.2012.00033>
39. Yu H, Littlewood T, Bennett M. Akt isoforms in vascular disease. Vascul Pharmacol. 2015 Aug 1;71:57-64. <https://doi.org/10.1016/j.vph.2015.03.003>
40. Karanovic D, Michelow IC, Hayward AR, DeRavin SS, Delmonte OM, Grigg ME, et al. Disseminated and congenital toxoplasmosis in a mother and child with activated PI3-kinase δ syndrome type 2 (APDS2): case report and a literature review of toxoplasma infections in primary immunodeficiencies. Front Immunol. 2019 Feb 14;10:425736. <https://doi.org/10.3389/fimmu.2019.00077>

Corrected Proof